Compare Ascendis Pharma A/S (ASND) vs Tractor Supply Co (TSCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Tractor Supply Co — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Tractor Supply Co trades at $30.5 (market cap $15.96B). The key difference: Ascendis Pharma A/S and Tractor Supply Co are close in size by market cap, and Tractor Supply Co pays a 3.15% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TSCO | |
|---|---|---|
Market Cap | $17.74B | $15.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $62.65 |
52-Week Low | $163.32 | $29.14 |
Enterprise Value | $18.11B | $22.14B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Tractor Supply (TSCO) trades at $30.43, up 1.0% on the day, with a bearish technical signal despite neutral oscillators. The company maintains stable revenue growth to $15.52B in 2025 with consistent $1.1B net income, though profit margins show slight compression. Recent earnings show mixed results with Q2 2026 expectations at $0.85 EPS. Analyst consensus is divided with 48% buy ratings and a $42.15 price target, representing 38% upside potential from current levels.
TSCO presents a compelling valuation case with P/E of 14.99 below industry averages, supported by strong ROE of 45.5% and dividend payments. Key risks include recent earnings misses, competitive retail pressures, and consumer spending sensitivity. The stock's current technical weakness near support at $29 creates potential entry opportunity for value-oriented investors seeking rural retail exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
